Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer

Register of interests (PDF 258 KB)

Final draft guidance (PDF 223 KB)

Committee papers (PDF 1.6 MB)

Public committee slides (long version) (PDF 567 KB)

Public committee slides (short version) (PDF 443 KB)

Final appraisal document - equality impact assessment (PDF 145 KB)

Final appraisal document - TA885 (PDF 293 KB)

Committee papers - ACM2 - TA885 (PDF 1.8 MB)

Public committee slides - ACM2 - TA885 (PDF 996 KB)

Final appraisal document - managed access agreement - TA885 (PDF 345 KB)

Final appraisal document - register of interests - TA885 (PDF 149 KB)

Final appraisal document - quality impact assessment - TA885 (PDF 153 KB)

Appraisal consultation document (PDF version) - TA885 (PDF 315 KB)

Committee papers - ACM1 - TA885 (PDF 6.73 MB)

Public committee slides - ACM1 - TA885 (PDF 967 KB)

Final scope - TA885 (PDF 193 KB)

Final stakeholder list - TA885 (PDF 163 KB)

Equality impact assessment (Scoping) - TA885 (PDF 124 KB)

NICE's response to comments on the draft scope and provisional stakeholder list - TA885 (PDF 244 KB)

Draft scope post referral - TA885 (PDF 203 KB)

Draft matrix post referral - TA885 (PDF 162 KB)